Independent Protection and Influence of the Spike-Specific Antibody Response of SARS-CoV-2 Nucleocapsid Protein (N) in Whole-Virion Vaccines

Molecular fate-mapping of serum antibody responses to repeat immunization

(2023) Ariën Schiepers et al.   NATURE

Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity

(2023) Rong Yue et al.   Vaccines

Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial

(2022) Haiping Chen et al.   VACCINE

Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models

(2022) Renee L. Hajnik et al.   Science Translational Medicine

Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong

(2022) Runhong Zhou et al.   The Lancet Regional Health Western Pacific

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

(2021) Piyada Supasa et al.   CELL

Coinfection with influenza A virus enhances SARS-CoV-2 infectivity

(2021) Lei Bai et al.   CELL RESEARCH

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

Emerging concepts in the science of vaccine adjuvants

(2021) Bali Pulendran et al.   NATURE REVIEWS DRUG DISCOVERY

Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity

(2021) William E. Matchett et al.   JOURNAL OF IMMUNOLOGY

Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2

(2021) Tanushree Dangi et al.   Cell Reports

B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19

(2021) Andreas Zollner et al.   EBioMedicine

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

(2021) Gang Zeng et al.   LANCET INFECTIOUS DISEASES

Covid‐19 vaccines and variants of concern: A review

(2021) Ikbel Hadj Hassine   REVIEWS IN MEDICAL VIROLOGY

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines

(2020) Weilong Shang et al.   npj Vaccines

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development

(2020) Noton K. Dutta et al.   JOURNAL OF VIROLOGY

Unbiased screens show CD8+ T cells of COVID-19 patients recognize shared epitopes in SARS-CoV-2, most of which are not located in the Spike protein

(2020) Andrew P. Ferretti et al.   IMMUNITY

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

(2020) Susanne H Hodgson et al.   LANCET INFECTIOUS DISEASES

Direct interaction of whole-inactivated influenza A and pneumococcal vaccines enhances influenza-specific immunity

(2019) Shannon C. David et al.   Nature Microbiology

Enhanced protective responses to a serotype-independent pneumococcal vaccine when combined with an inactivated influenza vaccine

(2016) Rachelle Babb et al.   CLINICAL SCIENCE

The Membrane Protein of Severe Acute Respiratory Syndrome Coronavirus Acts as a Dominant Immunogen Revealed by a Clustering Region of Novel Functionally and Structurally Defined Cytotoxic T‐Lymphocyte Epitopes

(2010) Jun Liu et al.   JOURNAL OF INFECTIOUS DISEASES